Vaccination

• 

  Subject Areas on Research

  • 17th Century Variola Virus Reveals the Recent History of Smallpox. 
  • A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques. 
  • A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease. 
  • A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. 
  • A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. 
  • A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. 
  • A program for eradication of hepatitis B from Taiwan by a 10-year, four-dose vaccination program. 
  • A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation. 
  • A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination. 
  • A statement regarding personal belief exemption from immunization mandates: from the Pediatric Infectious Diseases Society, March 2011. 
  • ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. 
  • Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele. 
  • Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. 
  • Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system. 
  • Addressing the vaccine confidence gap. 
  • Adenovirus F protein as a delivery vehicle for botulinum B. 
  • An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity. 
  • An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. 
  • An economic framework for preventive care advice. 
  • Analysis of Japanese encephalitis epidemic in Western Nepal in 1997. 
  • Analysis of factors influencing vaccine uptake: perspective from Spain. 
  • Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia. 
  • Association Between Parental HPV Knowledge and Intentions to Have Their Daughters Vaccinated. 
  • Association of vaccine-related attitudes and beliefs between parents and health care providers. 
  • Associations between obesity and receipt of screening mammography, Papanicolaou tests, and influenza vaccination: results from the Health and Retirement Study (HRS) and the Asset and Health Dynamics Among the Oldest Old (AHEAD) Study. 
  • Attitudes, Intentions, and Barriers Toward Influenza Vaccination Among Pregnant Korean Women. 
  • B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. 
  • B cell responses to the 2011/12-influenza vaccine in the aged. 
  • BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine. 
  • Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity. 
  • Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. 
  • Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. 
  • Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay. 
  • CD20 deficiency in humans results in impaired T cell-independent antibody responses. 
  • CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge. 
  • CXCL13 is a plasma biomarker of germinal center activity. 
  • Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. 
  • Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. 
  • Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop. 
  • Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge. 
  • Childhood Pneumonia. 
  • Childhood vaccine development: an overview. 
  • Cigarette smoking and hemagglutination inhibition response to influenza after natural disease and immunization. 
  • Clinical applications of a peptide-based vaccine for glioblastoma. 
  • Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques. 
  • Codelivery of Envelope Protein in Alum with MVA Vaccine Induces CXCR3-Biased CXCR5+ and CXCR5- CD4 T Cell Responses in Rhesus Macaques. 
  • Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research. 
  • Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. 
  • Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques. 
  • Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV. 
  • Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge. 
  • Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. 
  • Comprehension of a simplified assent form in a vaccine trial for adolescents. 
  • Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination. 
  • Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. 
  • Control of meningococcal disease in west Africa. 
  • Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. 
  • Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques. 
  • Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs. 
  • Cost-effectiveness evaluation of measles immunization strategies on a college campus. 
  • Cost-effectiveness of Strategies for Offering Influenza Vaccine in the Pediatric Emergency Department. 
  • Cost-effectiveness of a potential vaccine for Coccidioides immitis. 
  • Cost-effectiveness of a potential vaccine for human papillomavirus. 
  • Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. 
  • Countering Vaccine Hesitancy. 
  • Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. 
  • Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. 
  • Current immunotherapeutic strategies in colon cancer. 
  • Cutaneous complications of BCG vaccination in infants with immune disorders: two cases and a review of the literature. 
  • Cytokines: the future of intranasal vaccine adjuvants. 
  • DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA. 
  • DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant. 
  • DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. 
  • DNA vaccination by intradermal electroporation induces long-lasting immune responses in rhesus macaques. 
  • DNA vaccination. A clue to memory? 
  • DNA vaccines and immunity to herpes simplex virus. 
  • DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. 
  • Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. 
  • Detection of bloodstream pathogens in a bacille Calmette-Guérin (BCG)-vaccinated pediatric population in Malawi: a pilot study. 
  • Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. 
  • Development of a vaccine for the prevention of AIDS, a critical appraisal. 
  • Disparities in preschool immunization coverage associated with maternal age. 
  • Disseminated bacille Calmette-Guérin disease after vaccination: case report and review. 
  • Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. 
  • Does influenza vaccination or RSV prophylaxis impact resource utilization for children after the diagnosis of airway disorders? 
  • Drinking Water to Prevent Postvaccination Presyncope in Adolescents: A Randomized Trial. 
  • Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery. 
  • Dual functions of Lactobacillus acidophilus NCFM as protection against rotavirus diarrhea. 
  • Dysfunctional labor: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. 
  • Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. 
  • Economic analysis of influenza vaccination and treatment. 
  • Educational content and the effectiveness of influenza vaccination reminders. 
  • Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. 
  • Effect of influenza immunization on immunologic and virologic characteristics of pediatric patients infected with human immunodeficiency virus. 
  • Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination. 
  • Effect of patient reminder/recall interventions on immunization rates: A review. 
  • Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. 
  • Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions. 
  • Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. 
  • Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. 
  • Elimination of Perinatal Hepatitis B: Providing the First Vaccine Dose Within 24 Hours of Birth. 
  • End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. 
  • Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins. 
  • Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. 
  • Enhancement of cancer radiation therapy by use of adenovirus-mediated secretable glucose-regulated protein 94/gp96 expression. 
  • Epidemiology, Evolution, and Recent Outbreaks of Avian Influenza Virus in China. 
  • Estimated impact and cost-effectiveness of rotavirus vaccination in India: effects of geographic and economic disparities. 
  • Evaluating human papillomavirus vaccination programs. 
  • Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. 
  • Evaluation of vaccine-induced antibody responses: impact of new technologies. 
  • FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. 
  • Factors affecting influenza vaccination among attendees at a senior center. 
  • Family physician acceptance of universal hepatitis B immunization of infants. 
  • Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. 
  • Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. 
  • Fundamentals of Clinical Pharmacology With Application for Pregnant Women. 
  • Future vaccines and a global perspective. 
  • GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. 
  • Gene profiling of immune responses against tumors. 
  • Genomic correlates of variability in immune response to an oral cholera vaccine. 
  • HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. 
  • HIV vaccines: brief review and discussion of future directions. 
  • HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. 
  • HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. 
  • HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge. 
  • HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. 
  • HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. 
  • HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine. 
  • HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. 
  • HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. 
  • Haemophilus influenzae type b infections in Victoria, Australia, 1985 to 1987. 
  • Health Promotion Through Existing Community Structures: A Case of Churches' Roles in Promoting Rotavirus Vaccination in Rural Zambia. 
  • Hepatitis B vaccination and booster in predialysis patients: a 4-year analysis. 
  • Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens. 
  • Hepatitis B vaccines in patients with chronic renal failure before dialysis. 
  • Hepatitis B virus vaccine. An analysis of its potential use in medical workers. 
  • Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors. 
  • High intensive care unit admission rate for 2013-2014 influenza is associated with a low rate of vaccination. 
  • High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. 
  • High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. 
  • High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. 
  • Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. 
  • Human papillomavirus vaccine uptake among 9- to 17-year-old girls: National Health Interview Survey, 2008. 
  • Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses. 
  • Hurdles to herd immunity: Distrust of government and vaccine refusal in the US, 2002-2003. 
  • IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. 
  • Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. 
  • Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. 
  • Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. 
  • Immune selection after antigen-specific immunotherapy of melanoma. 
  • Immunization and MS: a summary of published evidence and recommendations. 
  • Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. 
  • Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. 
  • Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. 
  • Immunizations for preteens. 
  • Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. 
  • Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study. 
  • Immunogenicity of Haemophilus b conjugate vaccine (meningococcal protein conjugate) in children with prior invasive Haemophilus influenzae type b disease. 
  • Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. 
  • Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes. 
  • Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. 
  • Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. 
  • Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. 
  • Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. 
  • Immunological properties of bacterial DNA. 
  • Immunotherapy of surgical malignancies. 
  • Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. 
  • Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. 
  • Impact of patient education on influenza vaccine uptake among community-dwelling elderly: a randomized controlled trial. 
  • Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. 
  • Inactivated whole SIV vaccine in macaques: evaluation of protective efficacy against challenge with cell-free virus or infected cells. 
  • Incidence and severity of rotavirus and Escherichia coli diarrhoea in rural Bangladesh. Implications for vaccine development. 
  • Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice. 
  • Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. 
  • Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site. 
  • Increasing incidence of varicella hospitalizations in United States Army and Navy personnel: are today's teenagers more susceptible? Should recruits be vaccinated? 
  • Induction of immunity to human immunodeficiency virus type-1 by vaccination. 
  • Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. 
  • Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. 
  • Infections in Pregnancy and the Role of Vaccines. 
  • Influence of timing of seasonal influenza vaccination on effectiveness and cost-effectiveness in pregnancy. 
  • Influenza Adherence Tool Kit: Implementation and Evaluation Among Allogeneic Hematopoietic Transplantation Recipients
. 
  • Influenza vaccination in children with neurologic or neurodevelopmental disorders. 
  • Influenza vaccination of household contacts of newborns: a hospital-based strategy to increase vaccination rates. 
  • Informed consent and investigational new drug abuses in the U.S. military. 
  • Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. 
  • Intra-seasonal antibody repertoire analysis of a subject immunized with an MF59®-adjuvanted pandemic 2009 H1N1 vaccine. 
  • Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees. 
  • Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes. 
  • Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. 
  • Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue. 
  • Intranasal vaccination with the recombinant Listeria monocytogenes ΔactA prfA* mutant elicits robust systemic and pulmonary cellular responses and secretory mucosal IgA. 
  • Is developing an HIV-1 vaccine possible? 
  • Isolated abducens nerve palsy following neonatal hepatitis B vaccination. 
  • Keen on teen vaccines: improvement of adolescent vaccine coverage in rural North Carolina. 
  • Lack of effectiveness of a letter reminder for annual influenza immunization of asthmatic children. 
  • Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. 
  • Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251. 
  • Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination. 
  • Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. 
  • Long-term persistence of zoster vaccine efficacy. 
  • Low-Cost Intervention to Increase Influenza Vaccination Rate at a Comprehensive Cancer Center. 
  • MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. 
  • Malaria vaccine efficacy: the difficulty of detecting and diagnosing malaria. 
  • Mast cell-orchestrated immunity to pathogens. 
  • Maternal Effects of Respiratory Syncytial Virus Infection during Pregnancy. 
  • Maternal determinants of timely vaccination coverage among infants in rural Bangladesh. 
  • Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production. 
  • Measles Virus Hemagglutinin epitopes immunogenic in natural infection and vaccination are targeted by broad or genotype-specific neutralizing monoclonal antibodies. 
  • Media coverage of the measles-mumps-rubella vaccine and autism controversy and its relationship to MMR immunization rates in the United States. 
  • Medical Versus Nonmedical Immunization Exemptions for Child Care and School Attendance. 
  • Medicine. The need for a global HIV vaccine enterprise. 
  • Meningococcal immunisation in Ghana. 
  • Missed opportunities for adolescent vaccination, 2006-2011. 
  • Modeling of US Human Papillomavirus (HPV) Seroprevalence by Age and Sexual Behavior Indicates an Increasing Trend of HPV Infection Following the Sexual Revolution. 
  • Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. 
  • Modified varicella-like syndrome in children previously vaccinated with live attenuated measles, mumps, rubella and varicella vaccine. 
  • Modulation of alloimmunity to major histocompatibility complex class I by cotransfer of cytokine genes in vivo. 
  • Modulation of specific active immunization against murine melanoma using recombinant cytokines. 
  • Molecular analysis of adenovirus isolates from vaccinated and unvaccinated young adults. 
  • Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. 
  • Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. 
  • Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. 
  • Nasal peptide vaccination elicits CD8 responses and reduces viral burden after challenge with virulent murine cytomegalovirus. 
  • Nasal vaccination with troponin reduces troponin specific T-cell responses and improves heart function in myocardial ischemia-reperfusion injury. 
  • Navigating parental vaccine hesitancy. 
  • Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus. 
  • Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. 
  • Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. 
  • Nonmedical exemptions to school immunization requirements: secular trends and association of state policies with pertussis incidence. 
  • Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node. 
  • Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. 
  • Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. 
  • On-time vaccine receipt in the first year does not adversely affect neuropsychological outcomes. 
  • Optimization of mucosal responses after intramuscular immunization with integrase defective lentiviral vector. 
  • Oral immunogenicity of the plant proteinase bromelain. 
  • Outbreak of influenza in highly vaccinated crew of U.S. Navy ship. 
  • Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy. 
  • Parental refusal of vaccination and transplantation listing decisions: a nationwide survey. 
  • Parental vaccine concerns in Kentucky. 
  • Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. 
  • Peptide-conjugated PAMAM dendrimer as a universal DNA vaccine platform to target antigen-presenting cells. 
  • Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine. 
  • Persistence of antibody in healthcare workers vaccinated against hepatitis B. 
  • Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. 
  • Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. 
  • Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines. 
  • Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants. 
  • Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. 
  • Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. 
  • Pneumococcal Carriage and Vaccine Coverage in Retirement Community Residents. 
  • Polio--new challenges in 2006. 
  • Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells. 
  • Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. 
  • Positive antibody response to vaccination in adolescence predicts lower C-reactive protein concentration in young adulthood in the Philippines. 
  • Postimmunization reactions. 
  • Postpartum immunization. Report of a study. 
  • Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults. 
  • Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. 
  • Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. 
  • Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S. 
  • Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. 
  • Potential leukemia virus subunit vaccines: discussion. 
  • Practical Approaches to Optimize Adolescent Immunization. 
  • Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy. 
  • Predictors of H1N1 vaccination in pregnancy. 
  • Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. 
  • Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. 
  • Preventive care in relation to obesity: an analysis of a large, national survey. 
  • Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. 
  • Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. 
  • Private demand for cholera vaccines in Beira, Mozambique. 
  • Programmatic and research priorities for improving influenza immunization of pregnant women. 
  • Programmatic challenges in obtaining and confirming the pneumococcal vaccination status of cochlear implant recipients. 
  • Promoting Vaccine Confidence. 
  • Prospects for childhood immunization in the next decade. 
  • Protection against Mycobacterium avium by DNA vaccines expressing mycobacterial antigens as fusion proteins with green fluorescent protein. 
  • Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. 
  • Proteomic and immunologic analyses of brain tumor exosomes. 
  • Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis. 
  • Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. 
  • Quantifying the impact of accessibility on preventive healthcare in sub-Saharan Africa using mobile phone data. 
  • RNA Vaccination Therapy: Advances in an Emerging Field. 
  • Rational design of membrane proximal external region lipopeptides containing chemical modifications for HIV-1 vaccination. 
  • Receipt of Recommended Adolescent Vaccines Among Youth With Special Health Care Needs. 
  • Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. 
  • Recent changes in vaccination guidelines. An update on vaccines and target population initiatives. 
  • Recent progress in immune-based interventions to prevent HIV-1 transmission to children. 
  • Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer. 
  • Recommended Childhood and Adolescent Immunization Schedule-United States, 2017. 
  • Recommended Childhood and Adolescent Immunization Schedules: United States, 2019. 
  • Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. 
  • Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. 
  • Research on vaccines during pregnancy: protocol design and assessment of safety. 
  • Research on vaccines during pregnancy: reference values for vital signs and laboratory assessments. 
  • Revised recommendations for poliovirus immunization. 
  • Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity. 
  • Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. 
  • Risk prediction for Staphylococcus aureus surgical site infection following cardiothoracic surgery; A secondary analysis of the V710-P003 trial. 
  • Safety and Immunogenicity of DTaP5-IPV Compared With DTaP5 Plus IPV as the Fifth Dose in Children 4-6 Years of Age. 
  • Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario. 
  • Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. 
  • Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. 
  • Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children. 
  • Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. 
  • Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. 
  • Seasonal and novel H1N1 influenza vaccination at a children's hospital. 
  • Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine. 
  • Shigellosis in custodial institutions. 
  • Simian immunodeficiency virus DNA vaccine trial in macaques. 
  • Simian immunodeficiency virus DNA vaccine trial in macaques. 
  • Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. 
  • Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques. 
  • Some state vaccination laws contribute to greater exemption rates and disease outbreaks in the United States. 
  • Splenectomy as a Destination: Improving Quality of Care Among Asplenic Veterans Through a Travel Clinic. 
  • Standard definitions of adherence for infrequent yet repeated health behaviors. 
  • Strategies for eliciting HIV-1 inhibitory antibodies. 
  • Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection. 
  • Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. 
  • Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. 
  • Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. 
  • Superantigen enhanced protection against a weak tumor-specific melanoma antigen: implications for prophylactic vaccination against cancer. 
  • Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. 
  • Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. 
  • Support for immunization registries among parents of vaccinated and unvaccinated school-aged children: a case control study. 
  • Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. 
  • Systems biology of vaccination for seasonal influenza in humans. 
  • Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. 
  • Technology evaluation: CEA-TRICOM, Therion Biologics Corp. 
  • Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. 
  • The Advisory Committee on Immunization Practices recommendation regarding the use of live influenza vaccine: A rejoinder. 
  • The HIV-positive traveler. 
  • The HPV vaccine: are dosing recommendations being followed? 
  • The March towards a Vaccine for Congenital CMV: Rationale and Models. 
  • The Need to Optimize Adolescent Immunization. 
  • The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. 
  • The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. 
  • The economic impact of HPV vaccines: not just cervical cancer. 
  • The effect of antipyretics on immune response and fever following receipt of inactivated influenza vaccine in young children. 
  • The effect of patient education on pediatric immunization rates. 
  • The effect of timing of influenza vaccination and sample collection on antibody titers and responses in the aged. 
  • The impact of the 2004-2005 influenza vaccine shortage in the Veterans Health Administration. 
  • The importance of including swine and poultry workers in influenza vaccination programs. 
  • The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. 
  • The quest for an antibody-based HIV vaccine. 
  • The risk of measles, mumps, and varicella among young adults: a serosurvey of US Navy and Marine Corps recruits. 
  • The role of bacterial DNA in autoantibody induction. 
  • Timing of retroviral infection influences anamnestic immune response in vaccinated primates. 
  • Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis. 
  • Toward a vaccine against AIDS: rationale and current progress. 
  • Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. 
  • Travelers with sickle cell disease. 
  • Treatment of children with HIV infection. 
  • Trends in Otitis Media and Myringotomy With Tube Placement Among American Indian and Alaska Native Children and the US General Population of Children After Introduction of the 13-valent Pneumococcal Conjugate Vaccine. 
  • Tumor-dendritic cell fusion as a basis for cancer immunotherapy. 
  • Underimmunization at discharge from the neonatal intensive care unit. 
  • Update on immunizations in adults. 
  • Use of mobile phones for improving vaccination coverage among children living in rural hard-to-reach areas and urban streets of Bangladesh. 
  • Using private demand studies to calculate socially optimal vaccine subsidies in developing countries. 
  • Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure. 
  • Vaccination against Herpes Zoster and Postherpetic Neuralgia. 
  • Vaccination against herpes zoster in developed countries: state of the evidence. 
  • Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. 
  • Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. 
  • Vaccination establishes clonal relatives of germinal center T cells in the blood of humans. 
  • Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. 
  • Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. 
  • Vaccination to Prevent Cancer. 
  • Vaccination with 73kDa recombinant heavy chain myosin generates high level of protection against Brugia malayi challenge in jird and mastomys models. 
  • Vaccination with T cell-defined antigens. 
  • Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia. 
  • Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. 
  • Vaccination with the immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) induces virus-specific lymphoproliferation, but fails to protect against lethal challenge. 
  • Vaccinations for pregnant women. 
  • Vaccine adjuvants: Softness makes it better. 
  • Vaccine knowledge and practices of primary care providers of exempt vs. vaccinated children. 
  • Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. 
  • Vaccine safety: medical contraindications, myths, and risk communication. 
  • Vaccine-based immunotherapeutic approaches to gliomas and beyond. 
  • Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope. 
  • Vaccine-preventable diseases in pregnancy. 
  • Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children. 
  • Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. 
  • Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration. 
  • Viral infections after renal transplantation. 
  • What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling. 
  • Who will enroll? Predicting participation in a phase II AIDS vaccine trial. 
  • Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent. 
  • Workshop on immunizations in older adults: identifying future research agendas. 
  • Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. 
  • [Emerging adenovirus threats: should China develop a vaccine-oriented prevention strategy?]. 
  • [Vaccination of children. A resounding success from the 1980's]. 
• 

  Keywords of People

  • Cunningham, Coleen Kathryn, Professor of Pediatrics, Pathology
  • Ferrari, Guido, Associate Professor of Surgery, Molecular Genetics and Microbiology
  • Gunn, Michael Dee, Professor of Medicine, Immunology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Staats, Herman Ford, Professor of Pathology, Immunology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, in the School of Medicine, Immunology
  • Yancy Jr., William Samuel, Associate Professor of Medicine, Medicine, General Internal Medicine